Advertisement.

MESO Projected Dividend Yield

Sponsored ADR/Mesoblast Ltd ( NASDAQ : MESO )

Mesoblast has developed a range of late stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. Remestemcel-L is Co.'s first generation mesenchymal lineage stromal cell product platform and is being develop for the treatment of systemic inflammatory diseases including: pediatric steroid refractory acute graft versus host disease; acute respiratory distress syndrome; and biologic refractory inflammatory bowel disease. Rexlemestrocel-L is Co.'s second generation mesenchymal lineage precursor cell product platform and is being develop for the treatment of: chronic heart failure; and chronic low back pain due to degenerative disc disease.

20 YEAR PERFORMANCE RESULTS

MESO Dividend History Detail
MESO Dividend News
MESO Competitors News

# of Shares: 0

Closing Price: 11.76

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000